Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

Inclusion Criteria: * Age: 18 to 55 years old, both inclusive. * Gender: Male and/or non-pregnant, non-lactating female. * Female of child-bearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to first dosing day. They must be using an acceptable form of contraception. For female of child-bearing potential, acceptable forms of contraception include the following: * Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or * Barrier methods containing or used in conjunction with a spermicidal agent, or * Surgical sterilization or * Practicing sexual abstinence throughout the course of the study. * Female will not be considered of child-bearing potential if one of the following is reported and documented on the medical history: * Postmenopausal with spontaneous amenorrhea for at least one year, or * Spontaneous amenorrhea for more than 6 months and less than one year with Serum Follicular Stimulating Hormone (FSH) level \> 40 mIU/mL, or * Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or * Total hysterectomy and an absence of bleeding for at least 3 months. * BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5). * Non-smokers a…